ERAS stock forecast, quote, news & analysis
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers... Show more
Erasca, Inc. (ERAS) Stock Analysis: Pan-RAS Breakthrough Ignites Volatility
Key Takeaways
- Erasca's lead candidate ERAS-0015 demonstrated promising preliminary Phase 1 efficacy, including a 62% objective response rate (ORR) in non-small cell lung cancer (NSCLC) patients with KRAS mutations.
- Stock surged over 140% year-to-date amid pipeline optimism but experienced a sharp correction following data release, reflecting biotech sector volatility.
- Analysts maintain a strong buy consensus with average price targets around $18-20, citing robust clinical momentum.
- Q4 2025 earnings beat expectations, bolstering cash position post-$225 million follow-on offering.
- Key 2026 catalysts include additional ERAS-0015 data and expansion cohorts in the U.S. and China.
Current Market Snapshot
Erasca, Inc. (ERAS) has navigated intense volatility across recent trading sessions, propelled by anticipation surrounding its oncology pipeline. The stock achieved new multi-year highs amid heightened investor interest in RAS-targeted therapies, only to face a pronounced pullback as market participants digested fresh clinical insights. Trading volumes have spiked dramatically, underscoring shifting sentiment in the precision oncology space. Broader biotech trends and macroeconomic pressures have amplified price swings, yet underlying fundamentals tied to clinical progress continue to draw attention from growth-oriented investors. ERAS remains positioned within a dynamic 52-week range, balancing high-risk innovation with substantial upside potential.
Trending AI Robots
Tickeron hosts hundreds of AI Trading Bots programmed to trade thousands of different tickers across various market conditions, employing diverse strategies such as momentum trading, mean reversion, and pattern recognition over short-term, swing, or long-term timeframes. The curated Trending AI Robots section spotlights over 25 top performers out of more than 350 total bots, selected based on real-time metrics like win rates often exceeding 60%, average returns ranging from 20-50% annually for select models, profitable trade ratios, and Sharpe ratios above 1.5. These bots adapt to volatility, with some focusing on biotech sectors amid clinical catalysts. Explore the page to identify bots aligning with your risk tolerance and discover performance stats tailored to current trends.
Recent Developments Driving ERAS Price Action
Erasca, a clinical-stage precision oncology firm targeting the RAS/MAPK pathway—frequently mutated in hard-to-treat cancers—has seen its stock whipsaw in response to pipeline advancements and market dynamics over recent weeks. On March 12, 2026, the company reported Q4 2025 financials, posting an EPS of -$0.10, surpassing consensus estimates of -$0.11, which reinforced confidence in its cash runway extended by a $225 million follow-on offering earlier in the year. This beat contributed to upward momentum, alongside multiple analyst upgrades: H.C. Wainwright raised its price target to $20 from $15, Mizuho to $19, J.P. Morgan to $25 on March 18, and Guggenheim to $20, all maintaining buy ratings amid optimism for RAS inhibitors.
Pipeline momentum accelerated with a March 5 collaboration with Tango Therapeutics for a dual-target trial combining ERAS-0015 with Tango's assets in RAS-mutant tumors. Around April 20, Erasca expanded rights for ERAS-0015—a potentially best-in-class pan-RAS molecular glue—into China, Hong Kong, and Macau, broadening its global footprint and fueling speculation on commercialization pathways.
The pivotal catalyst arrived April 27, when Erasca unveiled preliminary Phase 1 dose-escalation data from the AURORAS-1 trial for ERAS-0015 in KRAS-mutant solid tumors. Highlights included a 62% confirmed ORR in NSCLC patients previously treated with KRAS G12C inhibitors, rapid ctDNA (circulating tumor DNA) clearance signaling deep responses, and durable disease control exceeding nine months in some cases. Safety appeared manageable, with primarily low-grade treatment-related adverse events (TRAEs) at recommended doses of 24-32 mg. Management positioned ERAS-0015 as differentiated from competitors like Revolution Medicines' candidates due to pan-RAS activity.
Prior to disclosure, ERAS hit a 52-week high of $24.28, reflecting YTD gains over 140% on pipeline hype. Post-release, shares plunged over 50% amid elevated volumes, attributed to profit-taking after the run-up, small cohort sizes (n<20 per arm), lingering dilution overhang, and sector rotation away from high-beta biotechs. No major safety red flags emerged, but the sell-off highlights investor caution in early-stage oncology amid competitive RAS landscape pressures.
2026 Outlook and Key Factors to Monitor
As Erasca advances through 2026, investors should track milestones in its RAS-focused pipeline, including additional AURORAS-1 data in the first half for ERAS-0015 monotherapy expansion and combination cohorts, alongside initial readouts for pan-KRAS inhibitor ERAS-4001 in BOREALIS-1. Geographic expansion into China could accelerate enrollment and address vast unmet needs in KRAS-mutant cancers like NSCLC and colorectal.
Rising competition in pan-RAS therapies from peers like Revolution Medicines and Amgen necessitates monitoring differentiation via potency, safety, and combination potential. Regulatory progress, such as IND (Investigational New Drug) filings and FDA feedback, will shape timelines. Macro factors—biotech funding environment, interest rates, and M&A (mergers and acquisitions) activity—could influence valuation. Strong cash reserves support runway into 2028, but burn rate amid trial ramp-ups warrants attention. Balanced growth hinges on confirmatory data validating early signals in larger cohorts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ERAS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ERAS turned positive on May 20, 2026. Looking at past instances where ERAS's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ERAS's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 15, 2026. You may want to consider a long position or call options on ERAS as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
ERAS moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ERAS advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 167 cases where ERAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where ERAS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ERAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ERAS broke above its upper Bollinger Band on May 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ERAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.099) is normal, around the industry mean (18.720). P/E Ratio (0.000) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.682). ERAS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (357.550).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ERAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology